Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Staging, Scripps Get NIDDK Grant for Genomic DNA Samples

NEW YORK, Feb. 4 - Molecular Staging of New Haven, Conn., and the Scripps Research Institute have won an award totaling up to $2.5 million from the National Institute of Diabetes and Digestive and Kidney disease (NIDDK) to produce large samples of genomic DNA for genetic disease studies, the company said today.


The purpose of the grant, which will be spread over two and a half years, is to provide academic researchers with DNA samples from well-characterized patient population groups, without having to pay private corporations that own most of these samples, according to Molecular Staging.


About 8,000 samples of genomic DNA will be taken from patient samples from Scripps collection, and will be made available to the scientific community. Ernest Beutler, chairman of the department of molecular and experimental medicine at Scripps, will supervise this process, making sure to only provide samples from patients who have given informed consent.


Molecular Staging will use its.REPLI-g whole genome amplification method in order to copy the samples, the company said.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.